First Horizon Corporation’s Celldex Therapeutics CLDX Stock Holding History

First Horizon Corporation’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$11K	Hold	333	–	–	﹤0.01%	669
2021 Q1	$6K	Hold	333	–	–	﹤0.01%	791
2020 Q4	$5K	Hold	333	–	–	﹤0.01%	798
2020 Q3	$4K	Buy	+333	New	+$3.9K	﹤0.01%	796

Other funds holding CLDX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

First Horizon Corporation's CLDX Position: Q2 2021 in Review

First Horizon Corporation held its Celldex Therapeutics (CLDX) position steady in Q2 2021 at 333 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #669.

First Horizon Corporation first reported a position in CLDX in Q3 2020 and has held it in 4 quarters since. 131 funds tracked by Wall St. Rank hold CLDX as of Q2 2021.

First Horizon Corporation held 333 shares of Celldex Therapeutics worth $11K as of Q2 2021.
First Horizon Corporation left its Celldex Therapeutics share count unchanged in Q2 2021.
Celldex Therapeutics made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2021, its #669 holding.
First Horizon Corporation first reported a position in Celldex Therapeutics in Q3 2020 and has held it in 4 quarters since.
131 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2021.

Based on First Horizon Corporation's 13F filing for Q2 2021, filed 9 Aug 2021.